NeoGenomics, Inc.NEONASDAQ
Loading
EBITDA Margin Over TimeContracting
Percentile Rank14
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Percentile
P14
Within normal range
vs 5Y Ago
-0.7x
Contraction
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM-5.31%-2221.8%
2024-0.23%+92.3%
2023-2.98%+81.6%
2022-16.15%-19.6%
2021-13.50%-272.2%
20207.84%-14.8%
20199.20%-19.9%
201811.49%+3.9%
201711.05%+6.3%
201610.39%-